The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalle, Jean-Hugues, Balduzzi, Adriana, Bader, Peter, Pieczonka, Anna, Yaniv, Isaac, Lankester, Arjan, Bierings, Marc, Yesilipek, Akif, Sedlacek, Petr, Ifversen, Marianne, Svec, Peter, Toporski, Jacek, Gungor, Taifun, Wachowiak, Jacek, Glogova, Evgenia, Poetschger, Ulrike, Peters, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796856/
https://www.ncbi.nlm.nih.gov/pubmed/32753706
http://dx.doi.org/10.1038/s41409-020-01014-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796856/
https://www.ncbi.nlm.nih.gov/pubmed/32753706
http://dx.doi.org/10.1038/s41409-020-01014-x

Ejemplares similares